Chronic subdural hematoma is one of the most frequent neurosurgical conditions. It is frequently encountered in elderly people, (usually, after minor head trauma) and in patients on long-term anticoagulation and long-term hemodialysis. Bilateral chronic subdural hematoma tended to occur more in patients with anticoagulant or antiplatelet therapy. Innate immune responses play an important role in the pathogenesis of chronic subdural hematoma. The most frequent presenting symptoms are headache, cognitive decline, and focal neurologic deficit. Cognitive decline includes confusional state, psychomotor slowing, gait abnormalities, and subacute dementia. Chronic subdural hematomas often present with atypical and unusual manifestations and can be difficult to diagnose. A high index of suspicion is needed to make the early diagnosis. Patients require surgical hematoma evacuation. The common surgical procedures for chronic subdural hematoma include twist drill craniostomy, burr hole evacuation, or craniotomy. Eighty percent of patients recover completely. Infrequently, hematoma may recur. Instillation of tissue plasminogen activator increases the volume of hematoma drained and significantly reduces the incidence of recurrence. A recent preliminary observation suggests that chronic subdural hematoma can be treated medically with tranexamic acid alone. Atorvastatin has recently been found effective in reducing chronic subdural hematoma. In this clinical summary, Dr. Ravindra Kumar Garg, Department of Neurology, King George’s Medical University, Uttar Pradesh in Lucknow, India, discusses the pathophysiology, clinical presentation, impact on outcome, and available treatments for chronic subdural hematoma.